EuroCoord – European network of
HIV/AIDS cohort studies for a global
co-ordination on clinical research
Caroline Sabin
EuroCoord Scientific Co-ordinator
UCL, London
Background

EU-funded NoE established by several of the biggest
HIV cohorts and collaborations within Europe

Funded for 5 years from January 2011

Aims to exploit the scientific strength of each
participating network, and build on
complementarities between them, to enhance the
research conducted across Europe, thus providing
‘added value’
Founding networks
IMIT AMACS ECS-Mo t he rs & ECS -Inf an ts NS HPC -Mo t he rs & NHP S-I n fan ts PISCI S
KOM P NET C ASC ADE A NR S CO2 SEROCO F r a nk fu r t HIV Co ho r t S t ud y S a n Ra ff ae le
ANRS CO1/CO10 EPF UK CHIC Athena ITLR-Mothers & ITLR-Infants Swiss HIV Cohort Study
ICC ANRS CO6 PRIMO Co-RIS MOCHIV-Mothers & MoCHIV-Infants The Italian MASTER Cohort
CHIPS ANRS CO4 French Hospital’s Database on HIV HIV-MIP-Mothers & HIV-MIP-Infants
GEMES-H ae mo A NR S CO3 AQUITAINE E u roSIDA Mad ri d Coho r t HIV Child re n VACH
M o d e n a C o h o r t S t u d y D a n i s h H IV S t u d y A NR S CO 8 C O PI LOT E I CONA S t . P i e r r e
Collaboration of Observational HIV Epidemiological Research Europe
Coordination: Copenhagen HIV Programme (CHIP) & Institut de Santé Publique,d'Epidémiologie et de Développement (ISPED)
23 beneficiaries from 16 countries (> 100 collaborating centres/third
parties), ensuring representativeness across Europe.
Key research aims
1. To improve the management and life of HIV-positive
individuals, by:






Characterising and modelling HIV-positive populations in Europe;
Improving understanding of pathogenesis;
Documenting uptake of and response to therapy;
Evaluating implications of long-term HIV infection and ART exposure;
Assessing implications of specific management strategies;
Analysing effects and improving management of hepatitis and
tuberculosis (TB) co-infection.
Key research aims
1. To improve the management and life of HIV-positive
individuals, by:






Characterising and modelling HIV-positive populations in Europe;
Improving understanding of pathogenesis;
Documenting uptake of and response to therapy;
Evaluating implications of long-term HIV infection and ART exposure;
Assessing implications of specific management strategies;
Analysing effects and improving management of hepatitis and
tuberculosis (TB) co-infection.
2. To develop and implement novel methodology,
research platforms and technologies
3. To establish training programmes to improve clinical
management and research skills
Workpackage structure
Workpackage structure
WP2: Training and outreach
 Build on existing training activities (e.g.
ACTIVATE, NEAT, CHAIN and within
networks) to augment and update skills of
health professionals and researchers
 Provide clinical management skills and
statistical/epidemiological training
Workpackage structure
WP3: Scientific oversight
 Co-ordinate scientific work to ensure
maximal synergy
 Facilitate translation of research into policy
 Facilitate collaboration with other EUfunded research networks (e.g. CHAIN)
Specialist subgroups

Pharmacokinetics and pharmacology

Immunology/HIV virology

Statistical methodology

Improving the management of hepatitis Co-infection
Workpackage structure
WP4: Data management
 Harmonize collection of data items
between cohorts/networks;
 Encourage discussion of data formats,
SOPs, protocols and quality assurance
checks
Characterising HIV populations








I MI T AMACS ECS-Mo t he rs & ECS -I nf an ts NS HPC -Mo t he rs & NHP S-I n fan ts PI SCI S
KO M P NET C ASC ADE A NR S CO 2 SERO CO F r a nk fu r t HI V Co ho r t S t ud y S a n Ra ff ae le
ANRS CO1/CO10 EPF UK CHIC Athena ITLR-Mothers & ITLR-Infants Swiss HIV Cohort Study

ICC ANRS CO6 PRIMO Co-RIS MOCHIV-Mothers & MoCHIV-Infants The Italian MASTER Cohort
CHIPS ANRS CO4 French Hospital’s Database on HIV HIV-MIP-Mothers & HIV-MIP-Infants
GEMES-H ae mo A NR S CO 3 AQ UI TAI NE E u roSI DA Mad ri d Coho r t HI V Child re n V ACH
M o d e n a C o h o r t S t u d y D a n i s h H I V S t u d y A N R S CO 8 C O PI LO T E I CO N A S t . P i e r r e
Collaboration of Observational HIV Epidemiological Research Europe
Coordination: Copenhagen HIV Programme (CHIP) & Institut de Santé Publique,d'Epidémiologie et de Développement (ISPED)

Timing of diagnosis/presentation in pregnancy
Vertical transmission despite PMTCT
Focus on Eastern European cohorts
Production of assay for incidence testing
Test new diagnoses in C&E Europe and estimate incidence
Contribution of primary infection to propagation of epidemic
Regional differences in populations
Adherence to guidelines and ART outcomes
Standardise definitions of late presentation
Epidemiology and temporal trends
Understanding pathogenesis








I MI T AMACS ECS-Mo t he rs & ECS -I nf an ts NS HPC -Mo t he rs & NHP S-I n fan ts PI SCI S
KO M P NET C ASC ADE A NR S CO 2 SERO CO F r a nk fu r t HI V Co ho r t S t ud y S a n Ra ff ae le
ANRS CO1/CO10 EPF UK CHIC Athena ITLR-Mothers & ITLR-Infants Swiss HIV Cohort Study
ICC ANRS CO6 PRIMO Co-RIS MOCHIV-Mothers & MoCHIV-Infants The Italian MASTER Cohort

CHIPS ANRS CO4 French Hospital’s Database on HIV HIV-MIP-Mothers & HIV-MIP-Infants
GEMES-H ae mo A NR S CO 3 AQ UI TAI NE E u roSI DA Mad ri d Coho r t HI V Child re n V ACH
M o d e n a C o h o r t S t u d y D a n i s h H I V S t u d y A N R S CO 8 C O PI LO T E I CO N A S t . P i e r r e
Collaboration of Observational HIV Epidemiological Research Europe
Coordination: Copenhagen HIV Programme (CHIP) & Institut de Santé Publique,d'Epidémiologie et de Développement (ISPED)

Drug classes & CD4 cell subset dynamics
CD4 cell subset changes in response to ART/virological failure
Host genetic factors
Predictors of tropism use and change
Long-term non-progression and elite control
HIV resistance and viral tropism
Ultrasensitive genotypic tests
Activated inflammation, coagulation and soluble plasma cancer
markers
European registry of HIV controllers
HIV-1 vs. HIV-2 progression
Treatment uptake and outcomes









I MI T AMACS ECS-Mo t he rs & ECS -I nf an ts NS HPC -Mo t he rs & NHP S-I n fan ts PI SCI S
KO M P NET C ASC ADE A NR S CO 2 SERO CO F r a nk fu r t HI V Co ho r t S t ud y S a n Ra ff ae le

ANRS CO1/CO10 EPF UK CHIC Athena ITLR-Mothers & ITLR-Infants Swiss HIV Cohort Study
ICC ANRS CO6 PRIMO Co-RIS MOCHIV-Mothers & MoCHIV-Infants The Italian MASTER Cohort
CHIPS ANRS CO4 French Hospital’s Database on HIV HIV-MIP-Mothers & HIV-MIP-Infants
GEMES-H ae mo A NR S CO 3 AQ UI TAI NE E u roSI DA Mad ri d Coho r t HI V Child re n V ACH
M o d e n a C o h o r t S t u d y D a n i s h H I V S t u d y A N R S CO 8 C O PI LO T E I CO N A S t . P i e r r e
Collaboration of Observational HIV Epidemiological Research Europe

Coordination: Copenhagen HIV Programme (CHIP) & Institut de Santé Publique,d'Epidémiologie et de Développement (ISPED)

Pharmacokinetics
Treatment in infants
Treatment interruption and outcomes of restarting ART
Pharmacovigilance; ART in pregnancy
Population effectiveness of ART management
Effect of HIV infection duration
Temporal/regional differences in timing of ART
Type of ART and outcomes
Frequency and outcomes of switching
Database of HIV drug resistance mutations
Robust clinical tool for expected CD4 response following cART
Implications of short-term antenatal ART
New collaborative themes

HIV and TB (WP 13)
- Monitor incidence, long-term prognosis and temporal changes
- Effects of anti-TB therapy and prophylaxis
- Impact on management of HIV
- Risk factors for IRIS

HIV and Migrants (WP 14)
- Determination of likely country of acquisition
- Identify barriers to prevention, testing and treatment
- Key HIV outcomes and relationship with country of habitation.

Modelling (WP 15)
- Develop existing computer simulation model to provide Europewide consensus estimates for rates of diagnosis, treatment
usage, resistance, pregnancy, AIDS/death etc.
Summary

HIV EuroCoord will strengthen European HIV cohort
research, by bringing it within a single pan-European
network of cohort studies

A multidisciplinary approach, and access to data
from >250,000 HIV-positive individuals, will allow us
to address key areas of research aimed at improving
the management and life of HIV-positive individuals

By utilising a common research platform, we will
ensure that the most complementary, collaborative
and competitive science is untaken
Acknowledgements
Executive Board: Geneviève Chêne, University of Bordeaux II, France; Dominique Costagliola, Institut National de la
Santé et de la Recherche Médicale, France Julia Del Amo, Instituto de Salud Carlos III, Spain; Carlo Giaquinto,
Fondazione PENTA, Italy; Di Gibb, Medical Research Council, UK; Jesper Grarup, Københavns Universitet, Denmark;
Ole Kirk, Københavns Universitet, Denmark; Bruno Ledergerber, University of Zurich, Switzerland; Laurence Meyer,
Institut National de la Santé et de la Recherche Médicale, France; Alex Panteleev, St. Petersburg City AIDS Centre,
Russian Federation; Andrew Phillips, University College London, UK, Kholoud Porter (Chair), Medical Research
Council, UK; Caroline Sabin (Scientific Coordinator), University College London, UK, Claire Thorne, University College
London, UK; Stephen Welch, Fondazione PENTA, UK.
Council of Partners: Jean-Pierre Aboulker, Institut National de la Santé et de la Recherche Médicale, France; Jan
Albert, Karolinska Institute, Sweden; Silvia Asandi , Romanian Angel Appeal Foundation, Romania; Geneviève Chêne,
University of Bordeaux II, France; Dominique Costagliola, INSERM, France; Antonella d’Arminio Monforte, ICoNA
Foundation, Italy; Stéphane De Wit, St. Pierre University Hospital, Belgium; Frank De Wolf (Chair), Stichting HIV
Monitoring, Netherlands; Julia Del Amo, Instituto de Salud Carlos III, Spain; José Gatell, Fundació Privada Clínic per a
la Recerca Bíomèdica, Spain; Carlo Giaquinto, Fondazione PENTA, Italy; Osamah Hamouda, Robert Koch Institut,
Germany; Igor Karpov, University of Minsk, Belarus; Bruno Ledergerber, University of Zurich, Switzerland; Jens
Lundgren, Københavns Universitet, Denmark; Ruslan Malyuta, Perinatal Prevention of AIDS Initiative, Ukraine; Claus
Møller, Cadpeople A/S, Denmark; Andrew Phillips , University College London, UK; Kholoud Porter, Medical Research
Council, United Kingdom; Maria Prins, Academic Medical Centre, Netherlands; Aza Rakhmanova, St. Petersburg City
AIDS Centre, Russian Federation; Jürgen Rockstroh, University of Bonn, Germany; Magda Rosinska, National Institute
of Public Health, National Institute of Hygiene, Poland; Claire Thorne, University College London, UK; Giota Touloumi,
National and Kapodistrian University of Athens, Greece; Alain Volny Anne, European AIDS Treatment Group, France.
External Advisory Board: David Cooper, University of New South Wales, Australia; Nikos Dedes, Positive Voice,
Greece; Kevin Fenton, Centers for Disease Control and Prevention, USA; David Pizzuti, Gilead Sciences, USA; Marco
Vitoria, World Health Organisation, Switzerland.
Secretariat: Kate Coughlin, MRC Clinical Trials Unit, UK; Michelle Ellefson, Københavns Universitet, Denmark; Silvia
Faggion, Fondazione PENTA, Italy; Richard Frost, MRC Regional Centre London, UK; Marie Reynolds, MRC Clinical
Trials Unit, UK; Christine Schwimmer, University of Bordeaux II, France; Martin Scott, UCL European Research &
Development Office, UK.
IMIT AMACS ECS-Mo t he rs & ECS -Inf an ts NS HPC -Mo t he rs & NHP S-I n fan ts PISCI S
KOM P NET C ASC ADE A NR S CO2 SEROCO F r a nk fu r t HIV Co ho r t S t ud y S a n Ra ff ae le
ANRS CO1/CO10 EPF UK CHIC Athena ITLR-Mothers & ITLR-Infants Swiss HIV Cohort Study
ICC ANRS CO6 PRIMO Co-RIS MOCHIV-Mothers & MoCHIV-Infants The Italian MASTER Cohort
CHIPS ANRS CO4 French Hospital’s Database on HIV HIV-MIP-Mothers & HIV-MIP-Infants
GEMES-H ae mo A NR S CO3 AQUITAINE E u roSIDA Mad ri d Coho r t HIV Child re n VACH
M o d e n a C o h o r t S t u d y D a n i s h H IV S t u d y A NR S CO 8 C O PI LOT E I CONA S t . P i e r r e
Collaboration of Observational HIV Epidemiological Research Europe
Coordination: Copenhagen HIV Programme (CHIP) & Institut de Santé Publique,d'Epidémiologie et de Développement (ISPED)
www.etudes.isped.u-bordeaux2.fr/cohere/
www.cphiv.dk/EuroSIDA/tabid/59.aspx
www.cascade-collaboration.org
www.pentatrials.org
www.EuroCoord.net or Contact info@EuroCoord.net